Zacks: Dova Pharmaceuticals Inc (DOVA) Receives Consensus Rating of “Strong Buy” from Analysts

Dova Pharmaceuticals Inc (NASDAQ:DOVA) has received a consensus broker rating score of 1.00 (Strong Buy) from the three brokers that cover the stock, Zacks Investment Research reports. Three analysts have rated the stock with a strong buy rating.

Analysts have set a 12 month consensus price objective of $35.67 for the company and are forecasting that the company will post ($0.36) earnings per share for the current quarter, according to Zacks. Zacks has also given Dova Pharmaceuticals an industry rank of 164 out of 265 based on the ratings given to its competitors.

A number of brokerages have recently issued reports on DOVA. BidaskClub upgraded Dova Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday. Jefferies Group upped their price objective on Dova Pharmaceuticals to $33.00 and gave the stock a “buy” rating in a research note on Tuesday, November 28th. Zacks Investment Research cut Dova Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, November 14th. Finally, Leerink Swann upgraded Dova Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $32.00 price objective on the stock in a research note on Tuesday, September 26th.

Shares of Dova Pharmaceuticals (NASDAQ DOVA) opened at $28.70 on Wednesday. Dova Pharmaceuticals has a 12 month low of $16.98 and a 12 month high of $32.75.

Dova Pharmaceuticals (NASDAQ:DOVA) last announced its quarterly earnings data on Thursday, November 9th. The company reported ($0.38) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.08). During the same period in the prior year, the company posted ($0.41) earnings per share. sell-side analysts anticipate that Dova Pharmaceuticals will post -1.51 EPS for the current year.

Several hedge funds have recently bought and sold shares of the stock. FMR LLC acquired a new position in shares of Dova Pharmaceuticals during the 2nd quarter worth approximately $43,969,000. Perceptive Advisors LLC increased its holdings in shares of Dova Pharmaceuticals by 2.8% during the 3rd quarter. Perceptive Advisors LLC now owns 1,754,015 shares of the company’s stock worth $42,587,000 after acquiring an additional 47,516 shares during the last quarter. Fosun International Ltd increased its holdings in shares of Dova Pharmaceuticals by 9.2% during the 3rd quarter. Fosun International Ltd now owns 710,000 shares of the company’s stock worth $17,239,000 after acquiring an additional 60,000 shares during the last quarter. Paulson & CO. Inc. acquired a new position in shares of Dova Pharmaceuticals during the 2nd quarter worth approximately $13,856,000. Finally, Wells Fargo & Company MN increased its holdings in shares of Dova Pharmaceuticals by 62.1% during the 3rd quarter. Wells Fargo & Company MN now owns 324,287 shares of the company’s stock worth $7,874,000 after acquiring an additional 124,287 shares during the last quarter. 26.20% of the stock is currently owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: “Zacks: Dova Pharmaceuticals Inc (DOVA) Receives Consensus Rating of “Strong Buy” from Analysts” was first reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this piece of content on another publication, it was illegally copied and reposted in violation of US & international copyright and trademark laws. The legal version of this piece of content can be viewed at https://ledgergazette.com/2018/01/17/zacks-dova-pharmaceuticals-inc-dova-receives-consensus-rating-of-strong-buy-from-analysts.html.

Dova Pharmaceuticals Company Profile

Dova Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is focused on acquiring, developing and commercializing drug candidates. The Company’s initial focus is on thrombocytopenia, a disorder characterized by a low blood platelet count. The Company is developing avatrombopag for treatment of thrombocytopenia in patients with chronic liver disease (CLD).

Get a free copy of the Zacks research report on Dova Pharmaceuticals (DOVA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Dova Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dova Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply